tbuckley/cabot-search huggingface dataset:
Factors associated with self-reported failure of binding release among ACL injured male and female recreational skiers: a catalyst to change ISO binding standards?
Authors: Gerhard Ruedl, Kenneth Helle, Katja Tecklenburg, Alois Schranz, Christian Fink, Martin Burtscher
Journal: British Journal of Sports Medicine (2015)

Background Female recreational skiers have twice the rate of knee injuries and three time the rate of ACL injuries compared with their male counterparts. Female skiers suffering from a knee injury reported a significantly higher proportion of failure of binding release than knee injured male skiers. Purpose To evaluate factors associated with failure of binding release among ACL injured male and female recreational skiers. Study design Cohort study. Methods Among a cohort of 498 recreational skiers (68% females) suffering from an ACL injury (complete rupture or partial rupture), age, sex, height, weight, self-reported skill level and self-reported risk taking behaviour, gear origin, ski length, date of last binding adjustment, perceived speed at the moment of injury, type of fall, and failure of binding release of the ski of the injured knee, were collected by questionnaire. Results Failure of binding release was reported within 78% of cases and was significantly higher for females compared to males (83 vs 66%, p&lt;0.001) with an adjusted OR of 2.7 (95% CI 1.7 to 4.4). A higher perceived speed at the moment of injury was significantly associated with a decreasing proportion of failure of binding release. A slow perceived speed was independently associated with failure of binding release (adjusted OR 2.0; 95% CI 1.2 to 3.5). There was a significantly higher proportion of failure of binding release during backward falling compared to forward falling (87 vs 72%, p=0.002); similarly, a higher proportion of failure of binding release occurred in cases of complete rupture compared with a partial tear of the ACL (81 vs 64%, p=0.001), respectively. Conclusions Among this cohort of ACL-injured skiers, failure of binding release was significantly associated with female sex, a slow perceived speed at the moment of injury and complete rupture of the ACL.
Haploidentical Allogeneic Stem Cell Transplantation in Poor Risk Cytogenetic Acute Myeloide Leukemia: Results in 33 Patients
Authors: Elisa Sala, Rasha Salama Mohamed, Matteo Giovanni Carrabba, Carlo Messina, Maria Teresa Lupo Stanghellini, Luca Vago, Francesca Pavesi, Mara Morelli, Sarah Marktel, Andrea Assanelli, Consuelo Corti, Jacopo Peccatori, Massimo Bernardi, Fabio Ciceri
Journal: Blood (2014)
Phase I clinical trial with floxuridine and high-dose continuous infusion of leucovorin calcium.
Authors: R D Levin, J H Gordon, W Simonich, A Mellijor, R Sanchez, R M Williams
Journal: Journal of Clinical Oncology (1991)

Sixty-two patients with metastatic disease were treated with continuous infusion folinic acid (leucovorin calcium; Lv) and 2-deoxy-5-fluorouridine (floxuridine; FUDR). Lv was given by constant intravenous (IV) infusion at 500 mg/m2/d, days 1 to 6, while FUDR was given by IV push, days 2 to 6, at 3:00 PM daily with doses ranging from 294 to 1,214 mg/m2/d. This program was well tolerated with dose-limiting toxicities of diarrhea and stomatitis, while hematologic toxicity was minimal. Eighty-two percent of the assessable patients (46 of 56) had failed at least one chemotherapy regimen. One complete remission lasting 9 months and 10 partial remissions ranging from 5 to 10 months were observed in this heavily pretreated patient population for an overall response rate of 20%. These data suggest that the combination therapy with Lv and FUDR may have clinical use. Because of differing patient sensitivity to this drug combination, the recommended dose of FUDR for the initial therapy cycle is 500 mg/m2/d, days 2 to 6, with subsequent escalation to 900 mg/m2/d in those patients without extreme sensitivity. Phase II studies are now in progress with these doses.
Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma
Authors: B. Chiang, Y.C. Kim, A.C. Doty, H.E. Grossniklaus, S.P. Schwendeman, M.R. Prausnitz
Journal: Journal of Controlled Release (2016)
The traumatic aftereffects of collision at sea
Authors: A Hoiberg, B G McCaughey
Journal: American Journal of Psychiatry (1984)

To determine the psychological effects of a maritime collision, the authors compared the performance and health of the officers and crews of the USS Belknap (N = 336) and the USS Yarnell (N = 387) during the 3 years after the Belknap's collision. Significantly more of the Belknap members were hospitalized or separated from service because of neuroses, and the men who had the highest percentage of psychiatric hospitalizations were the uninjured men who were evacuated, returned to the ship, then flown to the United States. Future disaster studies should evaluate the effectiveness of crisis intervention in reducing long-term psychological impairment.
Abstract 9648: Aldosterone Increases Transforming Growth Factor-{beta} Expression to Activate Autophagy and Increase Aortic Fibroblast Collagen Synthesis and Vascular Stiffness
Authors: Samantha Torquato, Bradley A Maron, Joseph Loscalzo, Jane A Leopold
Journal: Circulation (2013)

Elevated levels of aldosterone (ALDO) are associated with aortic remodeling and increased arterial stiffness; however, the role of fibroblasts in these processes remains unknown. Accordingly, human...
Cycle-Dependent Anticancer Drug Cytotoxicity in Mammalian Cells Synchronized by Centrifugal Elutriation<xref ref-type="fn" rid="FN2">2</xref>
Authors: R E Meyn, M L Meistrich, R A White
Journal: JNCI Journal of the National Cancer Institute (1980)

The cycle-dependent cytotoxicity of seven chemotherapy agents was compared with the use of subpopulations of Chinese hamster ovary cells separated into the various phases of the cell cycle by centrifugal elutriation. The proportion of cells killed by either beta-cytosine arabinoside or hydroxyurea agreed well with the proportion of S-phase cells in the treated subpopulations. Cell-cycle survival patterns were also determined for bleomycin (BLM), adriamycin (ADR), cis-diamminedichloroplatinum (II) (cis-DDP), Asaley, and Yoshi 864. Three of the agents (cis-DDP, Asaley, and Yoshi 864) had similar cell-cycle survival patterns in that they all preferentially killed cells in the G1 phase. In contrast, BLM preferentially killed cells in G2+M phase, whereas ADR was most cytotoxic to cells in middle to late S-phase. This investigation demonstrated that separation of cultured mammalian cells into the various cell-cycle phases by centrifugal elutriation allows the rapid determination of the phase-dependent cytotoxic effects exerted by chemotherapy agents.
Development of Thymic Neoplasms in Rats Inoculated With a Murine Leukemia Virus (Rauscher)&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: G. J. Victor Swaen
Journal: JNCI Journal of the National Cancer Institute (1966)

The lesions following inoculation of the Rauscher virus into newborn Osborne-Mendel rats are described. An early splenomegaly resulting from a hyperplasia of the blood-forming elements was found. The hyperplasia was chiefly erythroblastic. Later, an increased number of macrophages was found in the thymus, followed by an atrophy with nearly complete loss of thymic lymphocytes, and, finally, within the atrophied thymus malignant cells appeared. A variety of lymphocytic neoplasms was induced and also neoplasms apparently derived from the thymus epithelium. In all instances, the neoplastic cells first appeared in the thymus.
Membrane Antigen of Bovine Papilloma Virus-Induced Fibroma Cells2
Authors: S. W. Barthold, C. Olson
Journal: JNCI Journal of the National Cancer Institute (1974)

A surface antigen on live, unfixed, bovine papilloma virus-induced fibroma cells was demonstrated with the indirect immunofluorescence (IF) test. Sera from calves with experimentally produced fibromas contained antibody to cultured fibroma cells; this indicated exposure to the same antigen. No activity could be demonstrated with the same sera tested against cultured normal dermal fibroblasts. The serum antibody activity could be removed by absorption with tumor cells but not with normal cells. Cultured fibroma cells were negative for viral antigens by the direct IF test and electron microscopic examination. Sequential antibody titers indicated correlation with onset of tumor growth but not with progression or regression of fibromas.
Abstract 12749: Factors Influencing the Development of De Novo Heart Failure in Stage-B Asymptomatic Patients -A Report From the CHART-2 Study-
Authors: Tsuyoshi Takada, Yasuhiko Sakata, Satoshi Miyata, Jun Takahashi, Kotaro Nochioka, Masanobu Miura, Hiroaki Shimokawa
Journal: Circulation (2012)

Background: Since heart failure (HF) is an urgent public health issue worldwide, the AHA/ACC guidelines strongly recommend the importance to prevent the development of HF in asymptomatic Stage-B patients. However, little is known about the etiology and predictors for the development of de novo HF in stage B patients. Method: Among the 10,219 subjects registered in our cohort, named as the Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2) study, we first compared the demographics and clinical outcomes between the 4,463 Stage-B patients with asymptomatic cardiac structure abnormalities (mean age 67.3 years, male 71.2%) and the 820 Stage-A patients with coronary artery disease without cardiac dysfunction (mean age 69.0 years, 69.2% male). We then analyzed the predictors for de novo HF in Stage-B patients. Results: As an etiology, the prevalence of ischemic heart disease, valvular heart disease, and cardiomyopathy in Stage-B patients were 51.0, 19.1, and 10.0%, respectively. In St...
Abstract 16093: Very Low Rates of Vascular Complications Can Be Achieved After Transcatheter Aortic Valve Implantation(tavi) Performed With Surgical Femoral Access
Authors: Mariama Akodad, Erika Nogue, Nicolas Nagot, Jean-Christophe Macia, Thomas Gandet, Bernard Albat, Guillaume Cayla, Richard Gervasoni, Delphine Delseny, Florence Leclercq
Journal: Circulation (2014)

Objectives:  Access site vascular complications (VC) remain a major concern after Transcatheter Aortic Valve implantation (TAVI). We therefore evaluated results of an exclusive surgical strategy for both access and closure of the femoral artery after TAVI.   Methods:  Between 2010-2014, we conducted a monocenter registry which included consecutive patients who had a TAVI procedure via transfemoral access using low profile 18- to 20F sheath system. Surgical cutdown and closure of the femoral artery were used for all patients. VC associated with the TAVI access site were evaluated within 30 days and classified as major or minor according to the VARC(Valve Academic Research Consortium)definition.   Results:  The study enrolled 396 patients with median age of 84 years (IQR = 81-88) and included 218 (55.1%) women. The median Euroscore was 18.5% (IQR=11-23). An Edwards Sapiens or a Medtronic Corevalve prosthesis were used for respectively 72.5% (n=287) and 26.5% (n=105) of patients.  VC occurred in 20 patients (6%) with only 8 patients (2%) with major VC (table 1).  Transfusions were required in 57 patients (14%), with only one unit of red blood cells needed for the vast majority of patients.  The total length of the procedure was 68 +/- 15 minutes including 13 +/- 5 minutes for the surgical access. In hospital mortality was 3.2% (n=13). In multivariable analysis, only diabetes (OR 2.8 ; 1.1-6.7, p=0.02 ) and chronic kidney failure (OR 3.2 (1.1-9.5), p=0.04) were predictive of VC while sheath size (p=0.9), body mass index (p=0.74), sex (p=0.6), Euroscore (p=0.6) and lower limb arteriopathy (p=0.7) were not.   Conclusions:  Surgical vascular access for TAVI appears simple and feasable and is associated with a very low rate of major vascular complications. Direct comparison between the surgical and the percutaneous approach may be relevant, particularly for high risk bleeding patients.
Prevalence of Subclinical Rheumatic Heart Disease in Eastern Nepal: A School-Based Cross-sectional Study
Authors: Nikesh R. Shrestha, Prahlad Karki, Rajan Mahto, Keshar Gurung, Naveen Pandey, Krishna Agrawal, Martina Rothenbühler, Philip Urban, Peter Jüni, Thomas Pilgrim
Journal: JAMA Cardiology (2016)

IMPORTANCE

Although rheumatic heart disease has been nearly eradicated in high-income countries, 3 in 4 children grow up in parts of the world where it is still endemic.

OBJECTIVES

To determine the prevalence of clinically silent and manifest rheumatic heart disease as a function of age, sex, and socioeconomic status and to estimate age-specific incidence.

DESIGN, SETTING, AND PARTICIPANTS

In this school-based cross-sectional study with cluster sampling, 26 schools in the Sunsari district in Eastern Nepal with 5467 eligible children 5 to 15 years of age were randomly selected from 595 registered schools. After exclusion of 289 children, 5178 children were enrolled in the present study from December 12, 2012, through September 12, 2014. Data analysis was performed from October 1, 2014, to April 15, 2015.

EXPOSURES

Demographic and socioeconomic characteristics were acquired in a standardized interview by means of a questionnaire customized to the age of the children. A focused medical history was followed by a brief physical examination. Cardiac auscultation and transthoracic echocardiography were performed by 2 independent physicians.

MAIN OUTCOMES AND MEASURES

Rheumatic heart disease according to the World Heart Federation criteria.

RESULTS

The median age of the 5178 children enrolled in the study was 10 years (interquartile range, 8-13 years), and 2503 (48.3%) were female. The prevalence of borderline or definite rheumatic heart disease was 10.2 (95% CI, 7.5-13.0) per 1000 children and increased with advancing age from 5.5 (95% CI, 3.5-7.5) per 1000 children 5 years of age to 16.0 (95% CI, 14.9-17.0) in children 15 years of age, whereas the mean incidence remained stable at 1.1 per 1000 children per year. Children with rheumatic heart disease were older than children without rheumatic heart disease (median age [interquartile range], 11 [9-14] years vs 10 [8-13] years; P = .03), more commonly female (34 [64.2%] vs 2469 [48.2%]; P = .02), and more frequently went to governmental schools (40 [75.5%] vs 2792 [54.5%]; P = .002). Silent disease (n = 44) was 5 times more common than manifest disease (n = 9).

CONCLUSIONS AND RELEVANCE

Rheumatic heart disease affects 1 in 100 schoolchildren in Eastern Nepal, is primarily clinically silent, and may be more common among girls. The overall prevalence and the ratio of manifest to subclinical disease increase with advancing age, whereas the incidence remains stable at 1.1 per 1000 children per year. Early detection of silent disease may help prevent progression to severe valvular damage.
MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets
Authors: Vadim G. Dyomin, Nallasivam Palanisamy, Kenneth O. Lloyd, Katerina Dyomina, Suresh C. Jhanwar, Jane Houldsworth, R. S. K. Chaganti
Journal: Blood (2000)
Response of Plasma Histaminase Activity to Heparin in Normal Subjects and in Patients With Small Cell Carcinoma of the Lung 2 3
Authors: David S. Etinger, Stephen B. Baylin, Deanna Minaberry, Martin D. Abeloff, E. David Mellits
Journal: JNCI Journal of the National Cancer Institute (1978)

Plasma histaminase (PH) activity only partially reflected the consistently high activity of histaminase in tumor tissue of patients with small cell carcinoma of the lung (SCC). To determine whether heparin might release histaminase from tumor tissue into the circulation as It does from some normal tissues, we studied the response of PH activity to small doses of heparin in 41 patients with SCC and in 57 normal subjects. In patients with SCC, the initial mean PH activity (2.0 U/ml) was not different from that in normal subjects (1.7 U/ml). After heparin administration, the mean PH activity was no different between the 2 groups (patients with SCC, 3.1 U/ml; normal subjects, 3.5 U/ml). In both groups, the higher the initial PH activity, the greater the magnitude of the PH activity response to heparin. This relationship was linear (normal subjects, r=0.88; patients with SCC, r=0.91). However, in patients with SCC, the increase in post-heparin PH activity, as related to the basal levels, was significantly less than that in normal subjects (P<0.001 by analysis of covariance). The data suggested that heparin did not affect the release of histaminase from tumor tissue into plasma to the same degree as it promoted the enzyme's entry from normal tissue sources. The differences between the groups may enable us to differentiate between selected patients with SCC and normal subjects with borderline high PH activity values.
Oestrogen receptor expression in human breast cancer during long-term fulvestrant treatment
Authors: J. Robertson, E. Gutteridge, K. L. Cheung, S. Pinder, A. Wakeling
Journal: Journal of Clinical Oncology (2004)

536 Background: Fulvestrant (Faslodex) is an estrogen receptor (ER) antagonist with no agonist activity that reaches steady-state levels after 3–5 monthly intramuscular (IM) injections. Fulvestrant for 14–21 days prior to surgery for primary breast cancer (BC) caused a dose-dependant reduction in ER (Cancer Res 2001;61:6739–46). Here, we examine the long-term changes in ER levels in patients receiving fulvestrant as first-line endocrine therapy for locally advanced/metastatic BC. Methods: 30 patients with lesions suitable for biopsy were recruited. Fulvestrant was given as a monthly 250 mg IM injection. Biopsies were taken pre-treatment, after 4 weeks and 6 months of treatment, and at disease progression (PD). Changes in ER levels were analyzed using SPSS analysis. Tumors were assessed every 3 months using UICC criteria. Results: 23 patients had evaluable disease at 6 months: 5 had PD and 18 had clinical benefit (CB; complete response, n=1; partial response, n=5; stable disease ≥24 weeks, n=12). Overall, ER downregulation was seen at 4 weeks (p=0.016) and at 6 months (p=0.011) compared with pre-treatment samples. There was a trend for continued downregulation from 4 weeks (mean Hscore 170.8 [range 50–280]) to 6 months (mean Hscore 132.33 [range 0–260]). In patients who progressed de novo (n=5), there was no significant reduction in ER (p=0.461). In patients achieving CB, ER downregulation was statistically significant (p=0.029, 4 weeks; p=0.011, 6 months). In both groups (CB and PD) ER was present at the time of PD/resistance. Conclusion: This is the first dataset to show continued downregulation of the ER beyond the presurgical period and confirms that fulvestrant can maintain ER suppression for an extended time. At the current clinical dose (250 mg), fulvestrant showed good clinical activity. The presence of ER at PD supports the use of further endocrine therapies and also provides insights into possible mechanisms of resistance through growth factor receptor cross-talk. Ongoing studies are investigating whether loading dose/high-dose regimens lead to earlier/increased ER downregulation and further improvement of clinical activity. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca Astrazeneca AstraZeneca AstraZeneca
Suspected non-Alzheimer disease pathophysiology — concept and controversy
Authors: Clifford R. Jack, David S. Knopman, Gaël Chételat, Dennis Dickson, Anne M. Fagan, Giovanni B. Frisoni, William Jagust, Elizabeth C. Mormino, Ronald C. Petersen, Reisa A. Sperling, Wiesje M. van der Flier, Victor L. Villemagne, Pieter J. Visser, Stephanie J. B. Vos
Journal: Nature Reviews Neurology (2016)
Tyrosinase Activity and Isoenzyme Distribution Corresponding to Growth and Regression of Melanoma in Sinclair Miniature Swine&lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="fn3"&gt;3&lt;/xref&gt;
Authors: S A Kovacs, K M Geekie, R W Oxenhandler, P F Agris
Journal: JNCI Journal of the National Cancer Institute (1981)

Malignant melanomas have been shown to contain high levels of monophenol monooxygenase (tyrosinase) enzyme activity; the enzyme is responsible for melanin synthesis. The melanoma of Sinclair miniature swine has a high incidence of spontaneous regression and thus provides a unique system for analyzing changes in tyrosinase activity at various tumor stages. Three tumor stages (progressively growing tumors, partially regressed tumors, and fully regressed tumors) were analyzed for tyrosinase activity. The progressing tumors were 34-fold higher than were the partially regressed lesions and 400-fold higher than were the fully regressed tumors. Histologically, the decrease in enzyme activity correlated with a loss of tumor cells. Sequential biopsies of tumors during the course of tumor development showed a positive correspondence between tumor volume and tyrosinase activity for the early and late stages of tumor growth and regression. Electrophoretic separation of tyrosinase preparations revealed three major tyrosinase "isoenzymes" whose relative abundance fluctuated during developmental increases and decreases in enzyme activity.
The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer’s disease
Authors: Marina Saresella, Francesca La Rosa, Federica Piancone, Martina Zoppis, Ivana Marventano, Elena Calabrese, Veronica Rainone, Raffaello Nemni, Roberta Mancuso, Mario Clerici
Journal: Molecular Neurodegeneration (2016)

Interleukin-1 beta (IL-1β) and its key regulator, the inflammasome, are suspected to play a role in the neuroinflammation observed in Alzheimer's disease (AD); no conclusive data are nevertheless available in AD patients. mRNA for inflammasome components (NLRP1, NLRP3, PYCARD, caspase 1, 5 and 8) and downstream effectors (IL-1β, IL-18) was up-regulated in severe and MILD AD. Monocytes co-expressing NLRP3 with caspase 1 or caspase 8 were significantly increased in severe AD alone, whereas those co-expressing NLRP1 and NLRP3 with PYCARD were augmented in both severe and MILD AD. Activation of the NLRP1 and NLRP3 inflammasomes in AD was confirmed by confocal microscopy proteins co-localization and by the significantly higher amounts of the pro-inflammatory cytokines IL-1β and IL-18 being produced by monocytes. In MCI, the expression of NLRP3, but not the one of PYCARD or caspase 1 was increased, indicating that functional inflammasomes are not assembled in these individuals: this was confirmed by lack of co-localization and of proinflammatory cytokines production. The activation of at least two different inflammasome complexes explains AD-associated neuroinflammation. Strategies targeting inflammasome activation could be useful in the therapy of AD.